Seek Labs
Seek Labs is a biotechnology firm developing AI-powered discovery tools, CRISPR therapeutics, and instrument-free diagnostics for emerging disease response.
Secondary Market Price
How Seek Labs Measures Up
To help you manage your Seek Labs equity, Prospect has run the company through our machine learning model.
Prospect Rating
--
This rating reflects our belief in this company's potential to grow to that many times its current value in 4 years. For an employee with stock, this rating suggests a potential return on equity, but it also comes with some risk.
Exit Risk
--
Our rating is a reflection of the likelihood of this company achieving a liquidity event for its employees based on the quality of investors, funding stage, founders, and more.
Funding Stage
Series A
A company’s funding stage reflects how established it is, how quickly it is scaling, and the average impact an employee may have when joining.
Secondary Market Price Chart
Create a free account to unlock real-time secondary market prices and future projections of Seek Labs's value.
Sign up to Unlock the Latest DataData will be available soon.
Sign up to receive notifications when it is available.
Prospect Projected Future Seek Labs Prices
Prospect’s machine learning model has been trained on the same data top-tier investors use to project the likely range of outcomes for Seek Labs's equity. Create a free account to view 10th-90th percentile projections over 2, 4, and 6 years.
Powerful tools to earn more from your equity
Company Description
Seek Labs is a biotechnology company developing a suite of platforms for rapid disease response. The company's current work focuses on three main technologies: the BioSeeker™ Discovery Engine, an AI-powered platform for identifying genetic targets; PTAP™ Therapeutics, a class of programmable CRISPR-based medicines designed to disable diseases at the genomic level; and SeekIt™ Diagnostics, a self-contained, instrument-free molecular testing platform for use at the point of care. Alongside these platforms, the company maintains a Global Disease Atlas, an adaptive genomic map to guide therapeutic development. Seek Labs was established to address the gap between the speed of disease emergence and the ability to respond with effective diagnostics and treatments.
The company is currently focused on scaling its platforms for global deployment and is actively seeking partners in diagnostics, therapeutics, global health, and pandemic preparedness. The stated goal is to enable the development of precision treatments and diagnostics before diseases spread widely. Recent announcements include the publication of a peer-reviewed paper on a CRISPR-based therapeutic that proved effective against African Swine Fever, an editorial review on the future of CRISPR antivirals, and the release of its 2025 Innovation & Impact Report.
- Battery Ventures
- Conviction Partners
- Bob Muglia
- Mustafa Suleyman
- Tristan Handy
- Co-Founder, Brant McLellan
Peer Group Comparison
Vs Peer Group of >$4B Startups
Frequently Asked Questions
Joining Anduril as an employee is another way to acquire equity, typically through stock options included in compensation packages.
Is Seek Labs worth joining?
Deciding to join a startup like Seek Labs involves evaluating its potential and how its equity package aligns with your financial goals. Tools like Prospect can help you model the potential value of your equity compensation to make a more informed career decision.
What should I do with my Seek Labs stock?
Managing your Seek Labs stock requires a personalized strategy based on your financial situation and the company's performance. Platforms like Prospect offer customized option exercise and stock sale strategies to help you maximize your returns and minimize taxes.
Can you sell Seek Labs stock?
As a private company, selling Seek Labs stock is typically restricted to specific events like tender offers or on secondary markets, if available. Prospect provides tools to help you navigate these opportunities and decide how much to sell for optimal tax outcomes.
How can I find the value of my Seek Labs stock?
Valuing stock in a private company like Seek Labs is complex, as it isn't publicly traded and can be volatile. You can use a platform like Prospect, which uses machine learning models and VC data to project the future value of your shares.
What is Seek Labs's equity worth?
The worth of your Seek Labs equity depends on factors like the company's valuation, your number of shares, and potential dilution. To understand its potential future value, you can use Prospect's predictive models which analyze various data points to forecast a range of outcomes.
What is Seek Labs's stock ticker symbol?
Seek Labs does not have a stock ticker symbol because it is a private company and its shares are not traded on a public stock exchange. Ticker symbols are assigned only when a company undergoes an initial public offering (IPO).
Can I buy or sell Seek Labs stock?
Opportunities to buy or sell stock in a private company like Seek Labs are generally limited to employees or accredited investors during specific windows, such as funding rounds or secondary market transactions. Tools like Prospect can help employees decide when and how much to sell based on their financial goals and tax implications.
What is the criteria to buy or invest in Seek Labs stock?
Investing in a private company like Seek Labs is typically restricted to employees receiving equity compensation or accredited investors participating in funding rounds. If you are an employee, resources like Prospect can help you understand and manage your equity stake effectively.
